Generic Zometa Availability
Last updated on Apr 10, 2025.
Zometa is a brand name of zoledronic acid, approved by the FDA in the following formulation(s):
ZOMETA (zoledronic acid - injectable;intravenous)
-
Manufacturer: NOVARTIS
Approval date: August 20, 2001
Strength(s): EQ 4MG BASE/VIAL (discontinued) [RLD] -
Manufacturer: NOVARTIS
Approval date: March 7, 2003
Strength(s): EQ 4MG BASE/5ML (discontinued) [RLD] -
Manufacturer: NOVARTIS
Approval date: June 17, 2011
Strength(s): EQ 4MG BASE/100ML (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zometa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical products comprising bisphosphonates
Patent 7,932,241
Issued: April 26, 2011
Inventor(s): Glausch; Alexandra et al.
Assignee(s): Novartis AG (Basel, CH)A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
Patent expiration dates:
- February 5, 2028✓
- February 5, 2028
-
Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Patent 8,324,189
Issued: December 4, 2012
Inventor(s): Galli Bruno & Schran Horst F & Seaman John J
Assignee(s): Novartis Pharmaceuticals CorporationA method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.
Patent expiration dates:
- May 29, 2025✓
- May 29, 2025✓
- May 29, 2025✓
- May 29, 2025
-
Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Patent 8324189*PED
Issued: December 4, 2012
Inventor(s): Galli Bruno & Schran Horst F & Seaman John J
Assignee(s): Novartis Pharmaceuticals CorporationA method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.
Patent expiration dates:
- November 29, 2025✓
- November 29, 2025
More about Zometa (zoledronic acid)
- Zometa consumer information
- Check interactions
- Compare alternatives
- Reviews (44)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Drug class: bisphosphonates
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.